MTC-1203
preclinicaldrug program · high
Develop a disease-modifying therapeutic for neurodegenerative diseases by improving mitochondrial health and inhibiting pathological mitochondrial fragmentation and dysfunction.
First-in-class drug candidate described as an inhibitor of pathological mitochondrial fragmentation and mitochondrial dysfunction, based on technology developed at Stanford University and exclusively licensed from Stanford.
Preclinical evidence reported in Huntington's and Parkinson's disease animal models and in patient-derived cells across Huntington's disease, Parkinson's disease, and Alzheimer's disease.
Demonstrated in vivo efficacy in Huntington's and Parkinson's disease animal models and activity in patient-derived cells across HD, PD, and AD.